Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose topical XSTEM-VLU in difficult-to-heal venous leg ulcers
2024-518757-42-00Phase 2Completed
- Sponsor
- Xintela AB
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of XSTEM-VLU in stasis ulcer (2 arms), sponsored by Xintela AB. Primary endpoints: Safety and tolerability of XSTEM-VLU and Efficacy in venous leg ulcer healing. Started Oct 2024; status: completed.
02
Drugs
XSTEM-VLU
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2024-518757-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518757-42-00.